Delgocitinib

Chemical compound From Wikipedia, the free encyclopedia

Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[6] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[6] Delgocitinib is a Janus kinase inhibitor that works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[7]

Trade namesCorectim, others
Other namesJTE-052; JTE-052A
AHFS/Drugs.comMonograph
MedlinePlusa625094
Quick facts Clinical data, Trade names ...
Delgocitinib
Clinical data
Trade namesCorectim, others
Other namesJTE-052; JTE-052A
AHFS/Drugs.comMonograph
MedlinePlusa625094
Routes of
administration		Topical
ATC code
Legal status
Legal status
Identifiers
  • 3-[(3S,4R)-3-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H18N6O
Molar mass310.361 g·mol−1
3D model (JSmol)
  • C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2
  • InChI=1S/C16H18N6O/c1-11-8-22(13(23)2-5-17)16(11)4-7-21(9-16)15-12-3-6-18-14(12)19-10-20-15/h3,6,10-11H,2,4,7-9H2,1H3,(H,18,19,20)/t11-,16-/m0/s1
  • Key:LOWWYYZBZNSPDT-ZBEGNZNMSA-N
Close

Medical uses

In the EU and the US, delgocitinib is indicated for the topical treatment of moderate to severe chronic hand eczema in adults for whom topical corticosteroids are inadequate or inappropriate.[3][4]

Society and culture

In July 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Anzupgo, intended for the treatment of chronic hand eczema.[4][8] The applicant for this medicinal product is LEO Pharma A/S.[4] Anzupgo was authorized for medical use in the European Union in September 2024.[4][5]

Delgocitinib was approved for medical use in the United States in July 2025.[9]

References

Related Articles

Wikiwand AI